Journal article

BDNF VAL66MET polymorphism and memory decline across the spectrum of Alzheimer's disease

Yen Ying Lim, Simon M Laws, Stephanie Perin, Robert H Pietrzak, Christopher Fowler, Colin L Masters, Paul Maruff

Genes Brain & Behavior | WILEY | Published : 2021


The brain-derived neurotrophic factor (BDNF) Val66Met (rs6265) polymorphism has been shown to moderate the extent to which memory decline manifests in preclinical Alzheimer's disease (AD). To date, no study has examined the relationship between BDNF and memory in individuals across biologically confirmed AD clinical stages (i.e., Aβ+). We aimed to understand the effect of BDNF on episodic memory decline and clinical disease progression over 126 months in individuals with preclinical, prodromal and clinical AD. Participants enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study who were Aβ + (according to positron emission tomography), and cognitively normal (CN; n = 238), ..

View full abstract


Awarded by National Health and Medical Research Council (NHMRC)

Funding Acknowledgements

National Health and Medical Research Council (NHMRC), Grant/Award Numbers: GNT1162645, GNT1147465; Austin Health, CogState Ltd., Sarich Institute; Dementia Australia [DA]; Florey Institute, University of Melbourne; Edith Cowan University [ECU]; Australian Commonwealth Scientific Industrial and Research Organization [CSIRO]